Episode Details

The Cooper Companies, Inc. Q2 FY2026 earnings breakdown - conversational walkthrough with a price-aware verdict and Wall Street consensus comparison. THE CALL: HOLD (3/5 conviction, MODERATE) - CURRENT @ $62.13 - HOLD - BUY below $52.00 with $48.00 stop - AVOID above $90.00 TRIGGER: A confirmed CooperSurgical divestiture at a clean price is the bull catalyst that could re-rate the stock to the $75-85 range WINDOW: 12-18 months -- CooperSurgical resolution and continued MiSight ramp are the key value drivers TRACKER: chargedalpha.com WALL STREET CONSENSUS - Ratings: 8 Strong Buy / 6 Buy / 4 Hold / 0 Sell / 0 Strong Sell - BUY - Median 12-month price target: $80.00 (range $61 - $101) - Charged Alpha vs consensus: ALIGN THESIS Cooper Companies is a best-in-class contact lens franchise with a 10-streak beat record at a 38% discount to 52-week highs. The HOLD thesis: accumulate toward the $58 add-zone, wait for CooperSurgical strategic review resolution, and own the re-rating when the lens franchise trades at a pure-play multiple. Bull lever: MiSight myopia management TAM expansion across Asia and Europe (24% growth, $32M now, $500M+ addressable), MyDay double-digit growth reinforcing daily silicone hydrogel dominance, and a clean CooperSurgical divestiture at fair value -- combined could drive 30-50% upside from current levels. Key risk: CooperSurgical strategic review fails to attract a buyer at an acceptable price; Asia Pacific contact lens market softens further; tariff and freight costs compress Q3 gross margin more than the guided 66% floor; GAAP EPS losses extend if additional litigation charges emerge. QUALITY CHECK - Management quality grade: A- (Ten consecutive quarters beating consensus; FY2026 guidance raised; reorganization synergies driving 260bps non-GAAP operating margin expansion; CooperSurgical strategic review demonstrates portfolio optimization discipline) - Earnings quality grade: A- (Non-GAAP operating margin 27% with consistent organic revenue growth; GAAP-to-non-GAAP gap is a one-time litigation charge not operational; FCF generation constructive at $96M quarterly with annual guidance of $650M) CHAPTERS 0:00 Hook 0:31 S0b_Year 1:12 The Print 1:57 S1b_BeatDecomp 2:21 The Trend 3:08 The Segments 4:09 The FCF Bridge 4:52 S4b_MarginQual 5:42 Guidance & The Narrative Diff 6:31 S5b_Catalyst 7:08 Peer Dot-Plot 7:53 S6b_Valuation 8:35 Management & Earnings Quality 9:37 S8a_Call 10:02 S8b_Call KEY METRICS - Q2 FY2026 - Revenue: $1.08B (YoY +8.0%, beat est by +2.6%) - EPS: $1.21 (vs $1.10 est, beat +10.0%) - Operating margin: 27.0% - Free cash flow: $0.10B (8.9% margin) Cooper Companies Q2 FY2026 is a clean beat-and-raise on the metrics that matter. The contact lens business is winning -- MyDay daily silicone hydrogel growing double digits, MiSight pediatric myopia control up 24% to $32 million with Japan and Europe exceeding expectations, and the tenth consecutive quarter of beating consensus EPS. The GAAP EPS is negative due to the CooperSurgical litigation settlement, but that is a one-time item with 95% of claims resolved. The strategic review of CooperSurgical is the real story: if management executes a clean divestiture, COO becomes a pure-play premium contact lens company -- a business that could command 18-20x earnings versus today's 13.5x. At $62, down 38% from the 52-week high, the risk-reward is improving. HOLD with an eye toward adding below $58. NARRATIVE DIFF - what changed in management tone - Prior call: "On the Q1 FY2026 call, CEO Albert White highlighted CooperVision organic growth of 3% slightly below expectations due to Asia Pacific weakness and signaled the strategic review of CooperSurgical was in early stages." - This call: "Q2 FY2026 marks CooperVision's acceleration to 4% organic growth with MiSight's 24% ramp leading the way; CooperSurgical strategic review shows robust buyer interest with over 95% of litigation claims settled." - Tone shift: The c